Your browser doesn't support javascript.
loading
Real world data study of prevalence and direct costs related to dengue management in Brazil's private healthcare from 2015 to 2020
Abud, Denise Alves; Santos, Claudia Yang; Lobao Neto, Abner Augusto; Senra, Juliana Tosta; Tuboi, Suely.
  • Abud, Denise Alves; Takeda Pharmaceuticals Brazil. BR
  • Santos, Claudia Yang; Takeda Pharmaceuticals Brazil. BR
  • Lobao Neto, Abner Augusto; Takeda Pharmaceuticals Brazil. BR
  • Senra, Juliana Tosta; Takeda Pharmaceuticals Brazil. BR
  • Tuboi, Suely; Takeda Pharmaceuticals Brazil. BR
Braz. j. infect. dis ; 26(6): 102718, 2022. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1420719
ABSTRACT
ABSTRACT

Background:

The burden of dengue in Brazil is poorly documented and is based on data from the public health care setting. This study estimated the prevalence and costs of dengue management in the private health care system in Brazil from 2015 to 2020 using a large claims database from Orizon.

Methods:

We selected claims with dengue ICD codes (ICD-10 A90 or A91) from January 2015 to December 2020. Prevalence was estimated based on the population enrolled in health insurance plans in the given year. Costs were adjusted for the inflation up to December 2021 and evaluated by measures of central tendency and dispersion.

Results:

A total of 63,882 unique beneficiaries were included, with a total of 64,186 dengue cases. The year with the highest prevalence was 2015 (1.6% of patients who used health plans), and there was also an increase in cases in 2016 and 2019. The median cost per hospitalization in 2015 was US$486.17, and in 2020, it reached US$696.72. The median cost of a case seen at an emergency room ranged from US$ 97.78 in 2015 to US$ 118.16 in 2017.

Conclusions:

The estimated prevalence of dengue in this population of private health-insured patients followed the epidemiological trends of the general population in Brazil, with the highest rates in 2015, 2016, and 2019. The cost of dengue management has increased in the private health care setting over the years.


Texto completo: DisponíveL Índice: LILACS (Américas) Tipo de estudo: Avaliação Econômica em Saúde / Estudo de prevalência / Fatores de risco País/Região como assunto: América do Sul / Brasil Idioma: Inglês Revista: Braz. j. infect. dis Assunto da revista: Doenças Transmissíveis Ano de publicação: 2022 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: Takeda Pharmaceuticals Brazil/BR

Similares

MEDLINE

...
LILACS

LIS


Texto completo: DisponíveL Índice: LILACS (Américas) Tipo de estudo: Avaliação Econômica em Saúde / Estudo de prevalência / Fatores de risco País/Região como assunto: América do Sul / Brasil Idioma: Inglês Revista: Braz. j. infect. dis Assunto da revista: Doenças Transmissíveis Ano de publicação: 2022 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: Takeda Pharmaceuticals Brazil/BR